Berlin Fund Bets €100M on Consumer Health Revolution
Marvin Amberg, founder of naturalX Health Ventures - © Yves Callewaert
A new Berlin-based venture capital fund is making a bold move in the European consumer health space. As reported by Forbes, naturalX Health Ventures has raised €100 million to invest in companies that empower individuals to take control of their health journey.
Founded by Marvin Amberg, naturalX aims to fill a crucial gap in Europe's investment landscape. The fund targets businesses operating at the intersection of wellness and medicine, with a particular focus on preventative healthcare solutions.
"The consumer is becoming CEO of his or her own health," Amberg told Forbes, pointing to the increasing trend of individuals monitoring their own health data and proactively managing their wellbeing. This shift has been accelerated by the Covid-19 pandemic and the rise of wearable devices.
The fund, backed primarily by German pharmaceutical company Schwabe Group, has already made several strategic investments. These include mybacs, a digital probiotics platform, and Flow Neuroscience, which developed a depression-treating headset. The typical investment will range from €3 million to €5 million, primarily targeting Series A-stage companies.
The timing seems particularly relevant as European healthcare spending continues to rise. In Germany alone, healthcare costs now represent 12% of GDP, up from 8% in 1990. Yet only 3% of European healthcare spending goes toward preventative medicine – a gap that naturalX-backed companies aim to address.
